The Global mRNA Vaccines and Therapeutics market reached US$ 410 million in 2024 and is expected to reach US$ 503 million by 2032, growing at a CAGR of 9.0% during the forecast period 2025-2032.
mRNA vaccines and therapeutics represent a groundbreaking advancement in biotechnology, offering innovative solutions for a wide range of infectious diseases, genetic disorders, and cancer. Unlike traditional vaccines, which use weakened or inactivated virus particles to trigger immune responses, mRNA vaccines work by instructing cells to produce a protein that mimics the pathogen, thereby stimulating the immune system.